Spirocyclic NK1 antagonists I: [4.5] and [5.5]-Spiroketals
摘要:
A series of novel spiroketal-based NK1 antagonists is described. The effect of modifications to the spiroether ring and aromatic substituents are discussed, leading to the identification of compounds with high affinity and excellent CNS penetration. (C) 2002 Elsevier Science Ltd. All rights reserved.
Spirocyclic NK1 antagonists I: [4.5] and [5.5]-Spiroketals
摘要:
A series of novel spiroketal-based NK1 antagonists is described. The effect of modifications to the spiroether ring and aromatic substituents are discussed, leading to the identification of compounds with high affinity and excellent CNS penetration. (C) 2002 Elsevier Science Ltd. All rights reserved.
Metal-Free Three-Component Oxyalkynylation of Alkenes
作者:Yangshan Li、Ran Lu、Shutao Sun、Lei Liu
DOI:10.1021/acs.orglett.8b02954
日期:2018.11.2
An unprecedented (NH4)2S2O8 mediated metal-free three-componentalkene oxyalkynylation using H2O or alcohol as oxygenation agent is described. Mechanistic studies suggested that the reversed regioselectivity should be dictated by an alkene radical cation intermediate.
描述了前所未有的(NH 4)2 S 2 O 8介导的使用H 2 O或醇作为氧化剂的无金属三组分链烯氧基炔基化反应。机理研究表明,逆向的区域选择性应由烯烃自由基阳离子中间体决定。
Palladium(II)-catalyzed formation of γ-butyrolactones from 4-trimethylsilyl-3-alkyn-1-ols: Synthetic and mechanistic aspects
γ-butyrolactones are obtained in good yields from 4-trimethylsilyl-3-alkyn-1-ols via Wacker-type oxidation reaction. A mechanism is proposed for this transformation: it involves two successive trans-hydroxypalladations followed by a [PdXSiMe3] syn-elimination and explains why the presence of the silyl group is essential in such a process.
Spiroketal derivatives, compositions containing them and their use as
申请人:Merck Sharp & Dohme Limited
公开号:US05728695A1
公开(公告)日:1998-03-17
The present invention relates to spiroketal derivatives of formula (I) and pharmaceutically acceptable salts thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.9a, R.sup.9b, m and n are as defined in the specification, and to processes for their preparation, to intermediates used in their synthesis, to pharmaceutical compositions containing them, and to their use in therapy. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia. ##STR1##